A history of biopharmaceutics in the food and drug administration 1968-1993

AAPS Journal

Volumn 12, Issue 1, 2010, Pages 44-50

  Skelly, Jerome Philip ^a  

^a NONE   (United States)

Author keywords

Bioavailability; Bioequivalence; Biopharmaceutics; FDA; Pharmacokinetics; SUPAC

Indexed keywords

DIGOXIN; SULFANILAMIDE; THALIDOMIDE; THEOPHYLLINE; DRUG;

BIOEQUIVALENCE; CERTIFICATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MARKETING; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HISTORY OF MEDICINE; HUMAN; NONHUMAN; PHARMACEUTICS; PROFESSIONAL DEVELOPMENT; REVIEW; SCALE UP; ARTICLE; BIOAVAILABILITY; HISTORY; LEGAL ASPECT; METABOLISM; PHARMACOKINETICS; UNITED STATES;

BIOLOGICAL AVAILABILITY; BIOPHARMACEUTICS; CERTIFICATION; HISTORY, 20TH CENTURY; PHARMACEUTICAL PREPARATIONS; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77449083005     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9154-8     Document Type: Review

References (43)

1. Seife, M. Evolution of the principal US food & drug laws. In: Sharma KN, Sharma KK, Sen P, editors. Generic drugs, bioequivalence and pharmacokinetics: Proceedings of the Indo-US Symposium, New Delhi, University College of Medical Sciences, 1990. Ring Road, New Delhi 110-029: University College of Medical Sciences; 1990. p. 7-14.
2. U.S. Department of Health and Human Services. A brief history of the center for drug evaluation and research. 2009. http://www.fda.gov/cder/about/ history/Histext.htm. Accessed March 2009.
3. U.S. Department of Health and Human Services. A brief history of the center for drug evaluation and research. 2009. http://www.fda.gov/aboutFDA/ whatwedo/history/thisweek/ucm117833.htm.
4. Skelly JP. Bioavailability policies and guidelines; in industrial bioavailability and pharmacokinetics-guidelines and controls. In: Martin A, Doluisio JT, editors. College of pharmacy, drug dynamics institute. Austin: University of Texas; 1977. p. 2-41.
5. United States of America versus Pharmadyne Laboratories and Bernard Bedrick; United States District Court, District of New Jersey. 1980.
6. United States of America versus Premo laboratories, Inc. and Seymour Blackman; United States District Court, District of New Jersey. 1980.
7. Federal Register; Bioavailability and Bioequivalence Requirements; June 20, 1975. 40:26142-71.
8. Federal Register; Bioavailability and Bioequivalence Requirements; July 7, 1977. 42:1624-53.
9. Drug Bioequivalence. A Report for the Drug Bioequivalence Study Panel to the Office of Technology Assessment, Congress of the United States: July 1974.
10. Marcus A. An industrial view of the official compendia. In: Martin A, Doluisio JT, editors. Industrial bioavailability and pharmacokinetics- guidelines, regulations and controls. Austin: College of pharmacy, Drug Dynamics Institute; 1977. p. 223-32.
11. Vitti TG, Banes D, Byers TE. Bioavailability of Digoxin, Editorial, NEJM Nov. 1971;(25):1433-44.
12. J Lindenbaum MH Mellow MO Blackstone VP Butler 1971 Variation in biologic availability of digoxin from four products NEJM 285 1334
13. JG Wagner M Christensen E Sakmar D Blair JD Yates PW Willis AJ Sedman RG Stoll 1973 Equivalence lack in digoxin plasma levels JAMA 224 199 204 10.1001/jama.224.2.199 1:CAS:528:DyaE3sXkt1Oms7g%3D 4739492
14. WH Barr LM Gerbracht K Letcher M Plaut N Strahl 1972 Assessment of the biological availability of tetracycline products in man Clin Pharm Ther 13 97 1:CAS:528:DyaE38XhtlGqtb4%3D
15. AJ Glazko AW Kinkel WC Alegnani EL Holmes 1968 An evaluation of absorption of chloramphenicol preparations in normal human subjects Clin Pharm Ther 9 472 1:CAS:528:DyaF1cXksFSqsb8%3D
16. DC Blair RW Barnes EL Wildner WJ Murray 1971 Biologic availability of oxytetracycline HCl capsuls JAMA 215 252
17. 21 Code of Federal Regulations; §320.23. 1977; Basis for Demonstrating In-Vivo Bioavailability or Bioequivalence Requirements.
18. JP Skelly VP Shah C Peck 1065 Topical corticosteroid induced skin blanching-eye or instrument Arch Dermatol 1991 127
19. VP Shah C Peck JP Skelly 1989 Vasoconstriction-skin blanching; assay for glucocorticoids: a critique Arch Dermatol 125 1558 61 10.1001/archderm.125.11. 1558 1:STN:280:DyaK3c%2FlsFansw%3D%3D 2817920 (Pubitemid 19280893)
20. RB Stoughton 1087 Are generic formulations equivalent to trade name topical glucocorticoids Arch Dermatol 123 1312 4 10.1001/archderm.123.10.1312
21. AW McKenzie RB Stoughton 1962 Method for comparing percutaneous absorption of steroids Arch Dermatol. 86 741 6
22. Brodie BB, Heller WM, Bazel S, editors. Bioavailability of drugs. Basel: Karger; 1972.
23. JD Haynes 1983 FDA 75/75 rule: a response J Pharm Sci 72 99 100 10.1002/jps.2600720128
24. DL Schuirmann 1981 Aon hypothesis testing to determine if the mean of a normal distribution is contained in a known interval (Abstract) Biometrics 37 617
25. DJ Schuirmann 1987 A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability J Pharmacokinet Biopharm 15 657 80 10.1007/BF01068419 1:STN:280: DyaL1c3jtVajtQ%3D%3D 3450848
26. S Anderson WW Hauck 1990 Consideration of individual bioequivalence J Pharmacokinet Biopharm 18 259 73 10.1007/BF01062202 1:STN:280: DyaK3czjvFekuw%3D%3D 2380920
27. JW Poole 1969 Drug Inf Bull 3 8
28. Skelly JP. New FDA Digoxin Regulations. Presentation; Annual Conference, Association of Food and Drug Officials, Jost Farms, Lancaster, Pennsylvania. May 1974.
29. Federal Register January 22, 1974.
30. Federal Register February 1, 1974.
31. Skelly JP, Gonzalez MA. FDA update: dissolution testing: simple tool-important contribution. Eur J Biopharm. 1993;39(5):222-3.
32. 21 Code of Federal Regulations 310.500; Digoxin Products for Oral Use: Conditions.
33. JP Skelly 1977 Dissolution testing: need for standardization Pharm Tech 1 5 12
34. Wood J, Flora KP, Duma RJ. Tetracycline: another example of generic bioinequivalence. JAMA. 1978;239(18):1874-76.
35. Hendeles L, Weinberger G, Milavetz G, Hill M, Vaughn L. Food induced 'dose dumping' from a once-a-day theophylline product as a cause of theophylline toxicity. Chest. 1985;87:758-65.
36. JP Skelly WH Barr LZ Benet JT Doluisio G Goldberg DT Lowenthal JR Robinson VP Shah RJ Temple A Yacobi 1987 Report of the workshop on controlled release dosage forms: issues and controversies Pharm Res 4 1 75 7 10.1023/A:1016494314263 (Pubitemid 17050749)
37. JP Skelly GL Amidon WH Barr LZ Benet JE Carter JR Robinson VP Shah A Yacobi 1990 In vitro and in vivo testing and correlations for oral controlled/modified-release dosage forms Pharm Res 7 9 975 82 10.1023/A:1015970512368
38. JP Skelly VP Shah HI Maibach RH Guy RC Wester G Flynn A Yacobi 1987 FDA & AAPS report of the workshop on principles and practices of in vitro percutaneous and penetration studies: relevance to bioavailability and bioequivalence Pharm Res 4 3 265 7 10.1023/A:1016428716506
39. VP Shah GL Flynn RH Guy HI Maibach H Schaefer JP Skelly RC Wester A Yacobi 1991 In vivo percutaneous penetration/absorption Pharm Res 8 8 1071 5 10.1023/A:1015829729439 1:STN:280:DyaK38%2FitVKmtA%3D%3D 1924164
40. VP Shah KK Midha S Dighe I McGilveray JP Skelly A Yacobi T Layloff CT Viswanathan, et al. 1992 Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies Pharm Res 9 4 588 92 10.1023/A:1015829422034
41. JP Skelly JP Van Buskirk, et al. 1993 Workshop report: scale-up of immediate release oral solid dosage forms Pharm Res 10 313 6 10.1023/A:1018915700942 1:STN:280:DyaK3s3gsFKmtA%3D%3D 8456084 (Pubitemid 23041751)
42. JP Skelly JP Van Buskirk, et al. 1993 Scale-up of oral extended release dosage forms Pharm Res 10 1800 5 10.1023/A:1018946819849 1:STN:280: DyaK2c7jsVKhsw%3D%3D 8302770 (Pubitemid 24000370)
43. JP Van Buskirk, et al. 1994 Scale-up of liquid and semisolid disperse systems Pharm Res 11 1216 20 10.1023/A:1018913605176 (Pubitemid 24259867)